SK bioscience
A South Korean vaccine and biotech company, with innovative R&D and manufacturing systems, which spun out from SK chemicals in 2018.
The company developed the first Korean cell culture-based trivalent influenza vaccine in 2015, followed by the first cell culture-based quadrivalent influenza vaccine, the second shingles vaccine, and Korea's second varicella vaccine. Additionally SK bioscience has developed South Korea's first COVID-19 vaccine, 'SKYCovione' through global cooperation with the Bill & Melinda Gates Foundation, CEPI and GSK.
The company is expanding its R&D pipeline through global partnerships with public and private institutions, and is planning to commercialize a pneumococcal conjugate vaccine, cervical cancer vaccine, typhoid conjugate vaccine, and rotavirus vaccine.
Latest SK bioscience News & Features
24 February 2024
9 August 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze